# India Chikungunya Vaccine Market > India Chikungunya Vaccine Market Research Report By Product Technology (Live-Attenuated Virus Vaccines, Inactivated Viral Vaccine, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates, Others), By Age Group (Pediatric, Adult, Geriatric) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.04% - **2024:** $ 15 Million - **2025:** $ 16.51 Million - **2035:** $ 42.98 Million - **Key Players:** Sanofi (FR), Takeda Pharmaceutical Company (JP), Bharat Biotech (IN), GSK (GB), Merck & Co. (US), Pfizer (US), Novavax (US), Valneva SE (FR) **Report ID:** MRFR/Pharma/51607-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-chikungunya-vaccine-market-53368 --- ## Market Summary ## **India Chikungunya Vaccine Market Overview** As per MRFR analysis, the India Chikungunya Vaccine Market Size was estimated at 13.5 (USD Million) in 2023. The India Chikungunya Vaccine Market Industry is expected to grow from 15(USD Million) in 2024 to 51 (USD Million) by 2035. The India Chikungunya Vaccine Market CAGR (growth rate) is expected to be around 11.768% during the forecast period (2025 - 2035) **Key India Chikungunya Vaccine Market Trends Highlighted** The India Chikungunya Vaccine Market is witnessing several significant trends driven by the increasing awareness of vector-borne diseases among the population. Rising instances of Chikungunya outbreaks, particularly in urban areas, have intensified the demand for effective vaccines. Government initiatives aimed at strengthening vaccine development and distribution systems are essential market drivers. The Indian government has been actively promoting health campaigns to educate citizens about the prevention of mosquito-borne diseases, creating a favorable environment for the vaccination programs.  Furthermore, collaborations between public and private sectors are emerging to accelerate research and development in vaccine technology, enhancing product availability in the market.There have been live attenuated and recombinant vaccines developed recently, demonstrating the use of new methods in vaccine design. These changes are meant to improve the effectiveness and safety of vaccines so that people will accept them more willingly.  Furthermore, the increasing attention given to the provision of services through national health policies like the National Health Mission creates many opportunities to improve the entire vaccination system, which also benefits the Chikungunya Vaccine Market. Additionally, the growth of the population and urbanization in India has turned Aedes mosquito bites into a more serious concern for public health. The rising need for vaccination against Chikungunya, especially in susceptible regions, signals a potential for market growth. As healthcare facilities improve and access to vaccination becomes more widespread, the barriers that once hindered vaccine uptake are gradually being minimized. Overall, the India Chikungunya Vaccine Market is positioned for growth backed by policy support, technological innovations, and a heightened awareness of health among citizens. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **India Chikungunya Vaccine Market Drivers** **Rising Chikungunya Incidence in India** The increasing incidence of Chikungunya virus infections in India is one of the most significant drivers for the India Chikungunya Vaccine Market Industry. According to the Ministry of Health and Family Welfare, there were about 1,500 reported cases of Chikungunya in the year 2020 alone, which marked a considerable uptick compared to previous years. With the urbanization and the proliferation of mosquito breeding sites in urban and semi-urban areas, the risk of outbreaks is heightened. Furthermore, the World Health Organization has noted that cases of Chikungunya are expected to rise in areas of India with suitable environmental conditions, essentially creating demand for effective vaccination strategies. Additionally, initiatives by organizations such as the Indian Council of Medical Research (ICMR) underscore the importance of developing vaccines specifically targeting this growing health concern, with the potential for widespread immunization campaigns as a preventive measure. **Government Initiatives and Funding** The Indian government has been increasingly proactive in addressing vector-borne diseases, including Chikungunya. Significant funding and research initiatives have been allocated to the development of vaccines. Under the National Health Mission, the government has earmarked funds for Research and Development (R&D) focused on vector-borne diseases, which also includes efforts to address Chikungunya.  The Department of Biotechnology has also been active in promoting vaccine development projects in collaboration with various research institutions and pharmaceutical companies.This governmental support not only helps advance vaccine formulation but also encourages private investments into the India Chikungunya Vaccine Market Industry, reflecting the critical role that public policy has on industry growth. **Growing Awareness and Preventive Health Measures** The general public's rising awareness regarding Chikungunya and other vector-borne diseases is influencing market growth for vaccines. Public health campaigns by the Indian government and non-governmental organizations have been instrumental in educating citizens about the importance of vaccination and preventive health measures. For instance, recent surveys indicate that over 60% of urban populations are now aware of Chikungunya and its effects, as reported by the Ministry of Health. This heightened awareness leads to increased demand for vaccines, highlighting the potential for significant market expansion. Moreover, vaccination drives against Chikungunya facilitated by the government and healthcare institutions further emphasize the commitment to mitigate disease impact and promote healthier communities. **India Chikungunya Vaccine Market Segment Insights** **Chikungunya Vaccine Market Product Technology Insights** The India Chikungunya Vaccine Market, particularly in the Product Technology segment, encompasses a range of sophisticated vaccine types, each with its specific advantages and applications. Live-Attenuated Virus Vaccines are among the most promising types, known for eliciting strong and lasting immune responses, which can significantly enhance public health outcomes in regions prone to Chikungunya outbreaks. The Inactivated Viral Vaccine segment plays a crucial role in ensuring safety and effectiveness, appealing to health authorities looking to implement robust vaccination campaigns across India, where Chikungunya has been a noted concern in several states. Recombinant Viral Vaccines leverage advanced biotechnology to stimulate immune responses with reduced risk of side effects, and as India advances in its biopharmaceutical capabilities, this technology is expected to gain more traction. Chimeric-Alphavirus Candidates bring innovative approaches to vaccine development through genetic engineering, which can address the changing dynamics of virus pathogenicity. Lastly, the 'Others' category comprises innovative research avenues and experimental vaccine strategies that hold potential for future breakthroughs in Chikungunya immunity. As the India Chikungunya Vaccine Market progresses, the interplay of these diverse Product Technology avenues not only provides multiple options to combat the disease but also contributes to a comprehensive strategic framework for addressing growing health challenges in the region. The increasing incidence of Chikungunya cases raised considerable awareness and necessity for vaccines, enabling significant funding and support for research and development across these different product technologies.  As the market evolves, these technologies are anticipated to foster partnerships and collaborations among academic institutions, government health agencies, and the private sector, consolidating efforts towards a more health-secure future for populations at risk in India. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **Chikungunya Vaccine Market Age Group Insights** The Age Group segmentation of the India Chikungunya Vaccine Market plays a crucial role in addressing the needs of diverse populations. The pediatric segment holds significant importance as children are more susceptible to severe symptoms and complications from Chikungunya, necessitating targeted immunization efforts. Adults constitute a significant portion of the market, especially considering their active participation in outdoor activities, which increases exposure to mosquitoes. Furthermore, the geriatric segment is increasingly critical due to the rising elderly population in India, which faces a higher risk of morbidity from the disease. As a result of these demographic trends, the India Chikungunya Vaccine Market is adapting to cater to varying needs, developing innovative solutions tailored distinctly for these age groups. The expansion of immunization programs and health campaigns can enhance awareness and emphasize the importance of vaccination, leading to increased uptake across all age segments. Moreover, the overall growth of the healthcare infrastructure and community health initiatives within India further complements the ongoing efforts in this sector, driving advancements in vaccine accessibility and administration. **Chikungunya Vaccine Market Distribution Channel Insights** The India Chikungunya Vaccine Market primarily revolves around various Distribution Channels, which play a crucial role in ensuring vaccine accessibility to the population. Among these, Hospital Pharmacies are significant as they are often the first point of contact for patients seeking medical assistance and vaccinations. The presence of trained medical professionals in these facilities helps facilitate informed decisions on Chikungunya vaccination, thereby promoting wider adoption. Retail Pharmacies also hold an essential position in this market, providing convenient access to vaccines for the general public. With a growing prevalence of Chikungunya in India, the need for efficient distribution through retail channels is increasing, leading to enhanced vaccine availability in urban and rural areas alike. The 'Others' category might include government health initiatives, non-profit organizations, and online platforms, which diversify distribution and potentially reach underserved populations. This multi-channel approach in the India Chikungunya Vaccine Market not only promotes vaccine uptake but also addresses logistical challenges, forming a vital component of public health strategies to combat the disease.Understanding the dynamics and importance of each distribution channel is essential for stakeholders aiming to navigate the evolving landscape of the vaccine market effectively. **India Chikungunya Vaccine Market Key Players and Competitive Insights** The India Chikungunya Vaccine Market has witnessed significant developments in response to the rising demand for preventive healthcare measures against vector-borne diseases. Competitively, this market is shaped by various pharmaceutical and biotechnology firms that engage in extensive research and development (R&D) activities to introduce effective vaccines. The competition is characterized by collaborations, strategic alliances, and innovations aimed at bolstering public health initiatives.  The governmental focus on immunization drives, alongside increasing public awareness about chikungunya and its effects, further enhances the competitive landscape. Companies are exploring diverse formulations and delivery methods, seeking to differentiate their products while adhering to regulatory requirements. This dynamic environment is crucial for assessing market trends, understanding consumer preferences, and identifying potential growth opportunities.GlaxoSmithKline has a prominent presence in the India Chikungunya Vaccine Market, standing out for its vast experience in the pharmaceutical sector and robust portfolio.  The company leverages its strong research capabilities to develop vaccines that address emerging infectious diseases, with chikungunya being a strategic focus. GlaxoSmithKline has established partnerships with local health authorities to enhance the accessibility of its vaccines, fostering trust and brand loyalty among consumers. Its established distribution networks and emphasis on quality assurance contribute to its competitive edge in this segment. Moreover, the company supports vaccination programs that aim to educate the public and improve patient outcomes, positioning itself as a reputable player in India's healthcare system.Bharat Biotech is another key player in the India Chikungunya Vaccine Market, recognized for its commitment to innovation and public health.  The company has developed vaccines tailored to the unique epidemiological landscape of India, which includes a focus on chikungunya virus strains prevalent in the region. Bharat Biotech’s strengths lie in its advanced research facilities and its ability to conduct clinical trials that align with local needs. The establishment of strategic collaborations with government health agencies enhances its market presence, while ongoing investments in R&D promote the development of new products.  Bharat Biotech aims to expand its product line in the vaccine market, and its recent mergers and acquisitions have strengthened its operational capabilities and broadened its market reach, solidifying its position as a formidable contributor in efforts against chikungunya and other infectious diseases within India. **Key Companies in the India Chikungunya Vaccine Market Include** **India Chikungunya Vaccine Market Industry Developments** Recent developments in the India Chikungunya Vaccine Market have been dynamic, with advancements in vaccine Research and Development (R&D) spearheaded by key companies such as Bharat Biotech and Zydus Cadila. In September 2023, Bharat Biotech announced phase III clinical trials for its Chikungunya vaccine candidate, showcasing its commitment to combat this viral disease. Additionally, in November 2022, Dr. Reddy's Laboratories launched a joint initiative in collaboration with Indian Immunologicals to enhance vaccine accessibility. The government's push for vaccination amid rising Chikungunya cases has significantly impacted market growth, with an expectation of valuing the market at approximately USD 150 million by 2025.  Notably, mergers and acquisitions remain crucial for growth; however, there has been limited public information on recent activity among the major players in this sector. Companies like GlaxoSmithKline and Serum Institute of India continue to explore collaborations to boost production capabilities. The emphasis on strategic alliances indicates the potential for accelerated vaccine development, all while addressing ongoing public health concerns related to the disease. Overall, the Indian Chikungunya Vaccine Market is experiencing increased investments and initiatives by both the government and private sectors to enhance vaccine availability and efficacy. **India Chikungunya Vaccine Market Segmentation Insights** **Chikungunya Vaccine Market Product Technology****Outlook** **Chikungunya Vaccine Market Age Group****Outlook** **Chikungunya Vaccine Market Distribution Channel****Outlook** ## Market Drivers ### Public Health Campaigns Public health campaigns aimed at educating the population about chikungunya and its prevention are likely to significantly impact the chikungunya vaccine market. The Indian government, along with various health organizations, has initiated campaigns to raise awareness about the symptoms and transmission of chikungunya. These campaigns often emphasize the importance of vaccination as a key preventive measure. As a result, the chikungunya vaccine market may experience increased demand as more individuals become informed about the benefits of vaccination. Additionally, these campaigns often include community outreach programs, which can enhance accessibility to vaccines, particularly in rural areas. The potential for increased vaccination rates could lead to a reduction in disease transmission, further driving the market as public health initiatives gain traction. ### Rising Vector Control Initiatives The rise in vector control initiatives in India is expected to positively influence the chikungunya vaccine market. As chikungunya is primarily transmitted by Aedes mosquitoes, efforts to control mosquito populations are critical. Government and non-governmental organizations are increasingly investing in vector control programs, which often include public education on the importance of vaccination. These initiatives may lead to a synergistic effect, where increased vector control efforts complement vaccination campaigns. The chikungunya vaccine market could benefit from this dual approach, as communities become more engaged in both prevention strategies. Moreover, the potential for reduced transmission rates due to effective vector control could enhance public confidence in vaccination, further driving demand. ### Investment in Healthcare Infrastructure Investment in healthcare infrastructure in India is poised to play a crucial role in the growth of the chikungunya vaccine market. The government has been focusing on enhancing healthcare facilities, particularly in regions prone to outbreaks. This investment includes the establishment of vaccination centers and improved supply chains for vaccine distribution. As healthcare infrastructure improves, the accessibility of vaccines is likely to increase, encouraging more individuals to get vaccinated. Furthermore, the chikungunya vaccine market may see a boost from partnerships between public and private sectors aimed at expanding vaccination programs. With an estimated budget allocation of billions of dollars for healthcare improvements, the potential for a robust vaccination framework could significantly enhance the market landscape. ### Increased Incidence of Chikungunya Cases The rising incidence of chikungunya cases in India appears to be a primary driver for vaccine adoption. Reports indicate that the number of reported cases has surged, particularly during monsoon seasons, leading to heightened public concern. This increase in cases has prompted both healthcare providers and the government to prioritize vaccination as a preventive measure. The chikungunya vaccine market is likely to benefit from this trend, as more individuals seek vaccination to protect themselves from the debilitating effects of the virus. Furthermore, the economic burden associated with chikungunya, estimated at millions of dollars annually in healthcare costs, underscores the necessity for effective vaccination strategies. As awareness of the disease grows, the demand for vaccines is expected to rise, potentially leading to increased investments in vaccine development and distribution within the country. ### Collaboration with Pharmaceutical Companies Collaboration between the government and pharmaceutical companies is likely to be a significant driver for the chikungunya vaccine market. Such partnerships can facilitate research and development efforts, leading to the introduction of more effective vaccines. The Indian government has been actively seeking collaborations to enhance vaccine production capabilities, which could result in lower costs and increased availability. As pharmaceutical companies invest in the development of chikungunya vaccines, the market may see a surge in innovative solutions tailored to the Indian population. Additionally, these collaborations may lead to competitive pricing strategies, making vaccines more accessible to a broader segment of the population. The potential for increased production capacity and innovation could significantly shape the future landscape of the chikungunya vaccine market. ## Future Outlook The [Chikungunya Vaccine Market](https://www.marketresearchfuture.com/reports/chikungunya-vaccine-market-11066) is projected to grow at a 10.04% CAGR from 2025 to 2035, driven by rising disease prevalence, increased healthcare investments, and technological advancements. **New opportunities:** - Development of mobile vaccination units for remote areas - Partnerships with local governments for mass immunization campaigns - Investment in research for combination vaccines targeting multiple diseases By 2035, the chikungunya vaccine market is expected to achieve substantial growth and enhanced accessibility. ## Segment Insights ### By Product Technology: Live-Attenuated Virus Vaccines (Largest) vs. Recombinant Viral Vaccines (Fastest-Growing) In the India chikungunya vaccine market, the distribution of market share among product technologies reveals Live-Attenuated Virus Vaccines as the leading segment, commanding a significant share. This segment's established history and effectiveness make it a preferred choice among healthcare providers, contributing to its position as the largest technology. On the other hand, Recombinant Viral Vaccines are gaining traction, being recognized for their innovation and adaptability, leading to a growing market share in recent years. The growth trends in the product technology segment are driven by increasing investments in research and development, particularly for emerging technologies like Recombinant Viral Vaccines. This segment is notable for its rapid advancements aimed at enhancing vaccine efficacy and safety. Furthermore, factors such as rising awareness about chikungunya and the need for effective preventative measures are propelling demand, thus fostering innovation and expansion in the market. Live-Attenuated Virus Vaccines (Dominant) vs. Recombinant Viral Vaccines (Emerging) Live-Attenuated Virus Vaccines are characterized by their use of weakened forms of the virus, allowing for a robust immune response without causing disease. This technology is well-established, leading to its dominance in the market due to proven effectiveness and long-term immunity benefits. Conversely, Recombinant Viral Vaccines represent a newer approach, utilizing engineered viruses for targeted immune responses. They are recognized for their potential in overcoming limitations of traditional vaccines and are rapidly emerging in the market, supported by ongoing research and favorable regulatory environments, thereby appealing to healthcare providers seeking innovative solutions for chikungunya prevention. ### By Age Group: Pediatric (Largest) vs. Geriatric (Fastest-Growing) In the India chikungunya vaccine market, the distribution of market share among age segments reveals that the Pediatric segment accounts for the largest share, driven by increased awareness and vaccination drives targeting younger populations. The Adult segment follows closely, reflecting a growing concern for health among working professionals. Meanwhile, the Geriatric segment is emerging, albeit from a smaller base, suggesting shifts in health priorities as the aging population faces higher risks associated with chikungunya. Growth trends in the age group segment indicate a significant push towards vaccinating older adults, influenced by the increasing incidence of chikungunya in this demographic. Additionally, government initiatives aimed at improving vaccine accessibility and awareness are fostering growth in the Geriatric segment. The Pediatric segment, while currently leading, also benefits from sustained demand as parents prioritize preventative healthcare for their children. Overall, the focus is on broadening vaccine reach across all age groups, fostering a healthier population. Pediatric (Dominant) vs. Geriatric (Emerging) The Pediatric segment in the India chikungunya vaccine market is characterized by its established presence, largely due to robust immunization programs focusing on children. This segment enjoys the highest market share, attributed to proactive measures by health authorities to protect vulnerable populations. On the other hand, the Geriatric segment is emerging as a crucial player, driven by the increasing health demands of the aging population. The rise in chronic diseases among seniors, coupled with growing awareness of preventative healthcare, is pushing this segment forward. While still smaller, the Geriatric segment's dynamic growth is significant, as it reflects changing healthcare priorities and the need for tailored vaccine solutions for older adults. ### By Distribution Channel: Retail Pharmacies (Largest) vs. Hospital Pharmacies (Fastest-Growing) In the India chikungunya vaccine market, the distribution channel segment exhibits a varied landscape. Retail pharmacies hold the largest share, primarily due to their extensive presence and accessibility to the general population. They play a crucial role in providing vaccinations conveniently, contributing to their dominance in the market share. On the other hand, hospital pharmacies are gaining traction, leveraging their integrated healthcare services to enhance vaccination rates within clinical settings and thus capturing an increasing market share. Growth trends indicate a robust trajectory for both segment values. Retail pharmacies are experiencing consistent demand driven by heightened awareness of chikungunya and the surge in vaccination campaigns across the nation. Simultaneously, hospital pharmacies are positioned as the fastest-growing segment due to the increasing recognition of the importance of vaccinations during patient care, alongside strategic partnerships within healthcare institutions that bolster their distribution capabilities. Retail Pharmacies (Dominant) vs. Hospital Pharmacies (Emerging) Retail pharmacies are characterized by their widespread availability and convenience, making them the dominant channel in the India chikungunya vaccine market. They cater to a diverse demographic and facilitate easy access to vaccines, often driving public awareness campaigns. Hospital pharmacies, while emerging, are increasingly recognized for their vital role in patient care. They enhance the healthcare ecosystem by integrating vaccination services within hospitals, thus fostering trust and reliability. As governmental health initiatives promote vaccinations, hospital pharmacies are set to strengthen their market position significantly, bridging the gap between healthcare providers and patients. ## Competitive Benchmarking The chikungunya vaccine market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of vector-borne diseases and the urgent need for effective preventive measures. Key players such as Sanofi (France), Bharat Biotech (India), and Takeda Pharmaceutical Company (Japan) are actively shaping the market through strategic initiatives. Sanofi (France) focuses on innovation and research, particularly in developing next-generation vaccines, while Bharat Biotech (India) emphasizes local manufacturing capabilities to enhance accessibility. Takeda Pharmaceutical Company (Japan) is pursuing partnerships to expand its vaccine portfolio, indicating a collaborative approach to market penetration. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and regional responsiveness.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to meet the growing demand for chikungunya vaccines. The market appears moderately fragmented, with several players vying for market share. However, the influence of key players is substantial, as they leverage their resources and expertise to establish a foothold in various regions. This competitive structure suggests that while there is room for new entrants, established companies are likely to dominate through strategic positioning and operational efficiencies. In October Bharat Biotech (India) announced the launch of a new chikungunya vaccine aimed at enhancing immunogenicity and safety profiles. This strategic move is significant as it not only addresses the pressing health concerns associated with chikungunya but also positions Bharat Biotech as a leader in vaccine innovation within the region. The introduction of this vaccine could potentially increase market share and strengthen the company's reputation in the public health domain. In September Sanofi (France) entered into a collaboration with a leading research institution to develop a novel adjuvant for its chikungunya vaccine. This partnership is indicative of Sanofi's commitment to enhancing vaccine efficacy and could lead to improved market competitiveness. By investing in research and development, Sanofi aims to differentiate its offerings and respond to the evolving needs of healthcare providers and patients alike. In August Takeda Pharmaceutical Company (Japan) expanded its distribution network in India through a strategic alliance with local healthcare providers. This move is likely to enhance the accessibility of its chikungunya vaccine, thereby increasing its market presence. The partnership reflects a broader trend of companies seeking to strengthen their distribution channels to ensure that vaccines reach underserved populations, which is crucial for public health initiatives. As of November current trends in the chikungunya vaccine market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in vaccine development and distribution. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can effectively leverage these trends will likely secure a competitive advantage in the market. ## Recent News & Developments Recent developments in the India Chikungunya Vaccine Market have been dynamic, with advancements in vaccine Research and Development (R&D) spearheaded by key companies such as Bharat Biotech and Zydus Cadila. In September 2023, Bharat Biotech announced phase III clinical trials for its Chikungunya vaccine candidate, showcasing its commitment to combat this viral disease. Additionally, in November 2022, Dr. Reddy's Laboratories launched a joint initiative in collaboration with Indian Immunologicals to enhance vaccine accessibility. The government's push for vaccination amid rising Chikungunya cases has significantly impacted market growth, with an expectation of valuing the market at approximately USD 150 million by 2025.  Notably, mergers and acquisitions remain crucial for growth; however, there has been limited public information on recent activity among the major players in this sector. Companies like GlaxoSmithKline and Serum Institute of India continue to explore collaborations to boost production capabilities. The emphasis on strategic alliances indicates the potential for accelerated vaccine development, all while addressing ongoing public health concerns related to the disease. Overall, the Indian Chikungunya Vaccine Market is experiencing increased investments and initiatives by both the government and private sectors to enhance vaccine availability and efficacy. ## Report Scope | MARKET SIZE 2024 | 15.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 16.51(USD Million) | | MARKET SIZE 2035 | 42.98(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.04% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Sanofi (FR), Takeda Pharmaceutical Company (JP), Bharat Biotech (IN), GSK (GB), Merck & Co. (US), Pfizer (US), Novavax (US), Valneva SE (FR) | | Segments Covered | Product Technology, Age Group, Distribution Channel | | Key Market Opportunities | Emerging technologies in vaccine development enhance efficacy and accessibility in the chikungunya vaccine market. | | Key Market Dynamics | Rising demand for chikungunya vaccines driven by increased awareness and regulatory support for immunization initiatives. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the market valuation of the chikungunya vaccine market in 2024?** A: The market valuation of the chikungunya vaccine market was $15.0 Million in 2024. **Q: What is the projected market valuation for the chikungunya vaccine market by 2035?** A: The projected market valuation for the chikungunya vaccine market is $42.98 Million by 2035. **Q: What is the expected CAGR for the chikungunya vaccine market during the forecast period 2025 - 2035?** A: The expected CAGR for the chikungunya vaccine market during the forecast period 2025 - 2035 is 10.04%. **Q: Which companies are key players in the chikungunya vaccine market?** A: Key players in the chikungunya vaccine market include Sanofi, Takeda Pharmaceutical Company, Bharat Biotech, GSK, Merck & Co., Pfizer, Novavax, and Valneva SE. **Q: What are the different product technology segments in the chikungunya vaccine market?** A: The product technology segments include Live-Attenuated Virus Vaccines, Inactivated Viral Vaccines, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates, and Others. **Q: What was the valuation of the Recombinant Viral Vaccines segment in 2024?** A: The valuation of the Recombinant Viral Vaccines segment was $5.0 Million in 2024. **Q: How does the valuation of Adult vaccines compare to Pediatric vaccines in 2024?** A: In 2024, the valuation of Adult vaccines was $8.0 Million, significantly higher than the $3.0 Million valuation for Pediatric vaccines. **Q: What distribution channels are utilized in the chikungunya vaccine market?** A: Distribution channels in the chikungunya vaccine market include Hospital Pharmacies, Retail Pharmacies, and Others. **Q: What was the valuation of Retail Pharmacies in 2024?** A: The valuation of Retail Pharmacies in 2024 was $9.0 Million. **Q: What is the projected growth trend for the Geriatric segment in the chikungunya vaccine market?** A: The Geriatric segment is projected to grow from a valuation of $4.0 Million in 2024 to $11.48 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-chikungunya-vaccine-market-53368*